Established biopharmaceutical executive with more than 25 years of business development, corporate strategy, financing, and transaction experience Demonstrated leader in gene therapy and CNS drug development Appointment comes as Latus enters the clinic, with LTS-201 for Huntington’s disease on track for IND submission in 3Q 2026 PHILADELPHIA & BOSTON--(BUSINESS WIRE)--Latus…
Read More
Elsevier's ClinicalKey Al and Wei/sheet will deliver verifiable clinical evidence and patient context directly into the EHR, giving clinicians governed Al answers within their existing workflows NEW YORK, June 3, 2026 /PRNewswire/ -- Elsevier today announced it has acquired Wellsheet, a US-based health technology company that specializes in aggregating and…
Read More
lmmuno-oncology leader brings more than three decades of experience advancing innovative cancer therapies across biotech, pharma, and the National Cancer Institute HOUSTON, May 28, 2026 /PRNewswire/ -- lmmunoGenesis, a clinical-stage biotech company developing innovative, science-driven immunotherapies, today announced the appointment of Claudio Dansky Ullmann, M.D. as Chief Medical Officer. Dr…
Read More
Two appointments add drug development and defense-sector expertise to Ladder Bio’s Board as the company advances its Spiroligomer™ platform BLUE BELL, Pa.--(BUSINESS WIRE)--Ladder Bio, Inc., a structure-guided biotechnology company developing Spiroligomers™, a new class of chemical matter as medicines, today announced the appointments of Jay Fine, PhD, and John Prufeta…
Read More
Financing extension led by 8VC to advance LTS-201 as a potential significant commercial opportunity in Huntington’s disease (IND expected in 3Q 2026) Potential clinical proof-of-concept of Latus platform from LTS-101 in CLN2 disease expected in 4Q 2026; multiple fast follow-ons utilize the same capsid for larger indications Proprietary engineered AAV…
Read More
Computational and preclinical data support advancement of LTS-201 and LTS-101 programs into clinic later this year Latus founder Beverly Davidson, Ph.D., awarded the ASGCT Outstanding Achievement Award – the Society’s highest honor PHILADELPHIA & BOSTON--(BUSINESS WIRE)--Latus Bio, Inc. (Latus), a company advancing scalable genetic medicines for broad patient populations, today…
Read More
The Economic Times, US Story by Maitreyee Thakkar, Global Desk For decades, advances in battlefield medicine have focused on one goal: keep the wounded alive long enough to reach a surgical facility. Tourniquets, hemostatic dressings, rapid evacuation, and forward surgical teams dramatically improved survival in Iraq and Afghanistan. Yet one…
Read More
The acquisition brings together the gold standard for continuous ambulatory cough monitoring and lung sound analysis with proven remote spirometry and FeNO capabilities - creating a unique, single-partner endpoint solution for respiratory sponsors. PHILADELPHIA, PA / ACCESS Newswire / April 16, 2026 / Strados Labs, the respiratory endpoint intelligence company, today announced the…
Read More
Presentation details the IND-enabling work for IMGS-203, a potent Stimulator of Interferon Genes (STING) Agonist, for the treatment of Glioblastoma Multiforme (GBM) Houston, Texas, April 15, 2026 /PR Newswire/— ImmunoGenesis, a clinical-stage biotech company developing innovative, science-driven immunotherapies, today announced that it will present a poster at the upcoming American…
Read More
Leveraging AI-Driven Multiomics and Spatial Biology to Unlock the Full Potential of Next-Generation Cytotoxic Dual Checkpoint Inhibitor WALTHAM, Mass. & HOUSTON--(BUSINESS WIRE)--BostonGene, developer of the leading AI foundation model for tumor and immune biology, and ImmunoGenesis, a clinical-stage biotech company developing innovative, science-driven immunotherapies, today announced a strategic partnership to accelerate…
Read More